AveXis

What AveXis does

AveXis is a biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for patients with rare and life-threatening neurological genetic diseases, particularly spinal muscular atrophy (SMA). Founded in 2013 and headquartered in Dallas, Texas, AveXis developed Zolgensma (onasemnogene abeparvovec), an FDA-approved one-time intravenous gene therapy that delivers a functional copy of the SMN1 gene to address the genetic root cause of SMA. The company's core technology platform combines AAV capsid engineering for targeted gene delivery to muscle, heart, and CNS tissues with proprietary vector manufacturing capabilities, positioning Zolgensma as one of the only commercially available gene therapies for SMA globally. Zolgensma is priced at approximately $2.125 million per single-dose treatment, making it among the most expensive therapies in the world.

In May 2018, Novartis acquired AveXis for approximately $8.7 billion to gain access to its AAV gene therapy platform and lead asset Zolgensma. Following the acquisition, AveXis was integrated into Novartis Gene Therapies and its operations were consolidated into Novartis's San Diego genetic medicine research hub, alongside subsequent acquisitions of DTx Pharma (2023), Kate Therapeutics (2024), and Regulus Therapeutics (2024). The combined entity operates as part of Novartis's broader $23 billion US infrastructure commitment, which includes a $1.1 billion San Diego biomedical research hub announced in April 2025.

AveXis operates as a wholly-owned subsidiary of Novartis AG, with standalone financials no longer publicly reported. Its revenue model is built around one-time curative gene therapy treatments sold to healthcare providers and payers, supplemented by outcomes-based payment contracts, annuity-based installments, and state subscription programs designed to manage the upfront cost shock of million-dollar therapies. Customers include hospitals, specialty clinics, and treatment centers capable of administering intravenous gene therapy infusions, with the underlying patient population being infants and children diagnosed with SMA. Pre-acquisition, AveXis was listed on NASDAQ under ticker AVXS and raised approximately $75 million in venture funding prior to its acquisition.

Name

AveXis

Legal name

AveXis Inc.

Website

https://avexis.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

11–50 employees

Short description

AveXis is a clinical-stage gene therapy biotech developing AAV-based treatments for rare neurological genetic diseases, primarily Zolgensma for spinal muscular atrophy. Acquired by Novartis in 2018 for $8.7 billion, it now operates as part of Novartis Gene Therapies with consolidated San Diego research operations.

Ownership category

akta.pro rank

Product category

Gene Therapy Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

• Gene therapy
• Neuromuscular diseases
• AAV vector platform
• Rare disease treatment
• Spinal muscular atrophy

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Gene Therapy Product Sales: One-time curative gene therapy treatments sold to healthcare providers and payers, with Zolgensma priced at $2.125 million per treatment. Novartis Gene Therapies offers outcomes-based payment models to manage the upfront cost shock of these therapies.
2. Outcomes-Based Payment Contracts: Alternative payment models including annuity-based installments, outcomes-based contracts, and state subscription programs to help health systems manage budget impacts of million-dollar gene therapies.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

AveXis develops and manufactures AAV-based gene therapies for patients with rare and life-threatening neurological genetic diseases. Its flagship product Zolgensma (onasemnogene abeparvovec) is an FDA-approved one-time intravenous gene therapy that delivers a functional copy of the SMN1 gene to treat spinal muscular atrophy (SMA). Following its 2018 acquisition by Novartis, AveXis now operates as part of Novartis Gene Therapies, with its pipeline and technology consolidated under Novartis's San Diego genetic medicine research operations.

Product overview

AveXis is a gene therapy company that was acquired by Novartis in 2018 and now operates as Novartis Gene Therapies. The company's core product is Zolgensma, an FDA-approved gene therapy for spinal muscular atrophy (SMA). AveXis developed AAV (adeno-associated virus) vector-based gene therapies focused on treating severe genetic diseases, particularly neurological conditions. The company operates as part of Novartis's consolidated genetic medicine research in San Diego, which includes capabilities in gene therapy and xRNA technologies.

Differentiator

Problem solved

Functional benefit

Brands

• Novartis Gene Therapies: Novartis's gene therapy business unit incorporating AveXis programs including Zolgensma (onasemnogene abeparvovec-xioi), approved for spinal muscular atrophy (SMA).

Products and services

• Zolgensma (onasemnogene abeparvovec) A one-time intravenous AAV gene therapy that delivers a functional copy of the SMN1 gene to address the genetic root cause of spinal muscular atrophy (SMA). Zolgensma is AveXis's flagship product, priced at approximately $2.125 million per patient, and is administered in clinical settings to infants and children with SMA.

Quantifiable outcome

• Zolgensma achieves FDA approval and has become standard of care for SMA treatment globally

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Kate TherapeuticscoreStrategic or Co-development Partner · 1 January 2024Novartis acquired Kate Therapeutics in 2024 to expand its gene therapy and xRNA portfolio. The company brought additional delivery technologies and programs targeting muscle, heart, and CNS tissues.
• Regulus TherapeuticsminorStrategic or Co-development Partner · 1 January 2024Novartis expanded its San Diego footprint through the acquisition of Regulus Therapeutics, strengthening capabilities in gene therapy and xRNA research.
• DTx PharmacoreStrategic or Co-development Partner · 1 January 2023Novartis acquired DTx Pharma in 2023 to strengthen its xRNA capabilities. The acquisition brought additional expertise and programs to the consolidated San Diego genetic medicine research team.
• Novartis (acquirer)coreStrategic or Co-development Partner · 1 January 2018Novartis acquired AveXis in 2018 for its gene therapy capabilities, integrating the company's AAV technology platform and Zolgensma product into Novartis Gene Therapies. The acquisition brought programs and expertise targeting neuromuscular and neurodegenerative diseases.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sarepta Therapeutics: Sarepta is the most directly comparable AAV gene therapy company, with FDA-approved Elevidys for Duchenne muscular dystrophy (DMD) and an AAV platform targeting neuromuscular disease — directly overlapping AveXis's neuromuscular/CNS AAV gene therapy focus and competing for the same specialized treatment-center infrastructure.
• BioMarin Pharmaceutical: BioMarin is a rare-disease specialist with an AAV gene therapy (Roctavian for hemophilia A) and a deep pipeline of high-cost one-time treatments, directly comparable to AveXis/Novartis on commercial model, rare-disease commercial infrastructure, and AAV gene therapy manufacturing.
• Regenxbio: Regenxbio develops AAV-based gene therapies (e.g., ABECMA-derivative programs, ABTYS) using proprietary NAV capsid technology — a direct AAV platform competitor to AveXis, sharing the same delivery-technology category and serving overlapping rare-disease indications.
• uniQure: uniQure is a clinical-stage AAV gene therapy company developing treatments for CNS, cardiovascular, and metabolic rare diseases (e.g., AMT-130 for Huntington's). Its AAV platform and neuromuscular/neurodegenerative focus overlap directly with AveXis's pipeline breadth beyond SMA.
• Voyager Therapeutics: Voyager is an AAV gene therapy company developing treatments for CNS and neurodegenerative diseases (e.g., Alzheimer's, Parkinson's, tauopathies). Its CNS-focused AAV platform directly competes with AveXis's CNS capsid engineering programs.

Broad incumbents

• Biogen: Biogen markets Spinraza, the leading antisense oligonucleotide treatment for SMA and Zolgensma's primary competitor in the SMA market. While not an AAV platform peer, Biogen directly contests AveXis's core commercial franchise and operates an overlapping rare/neurological disease commercial infrastructure.
• Roche (Genentech): Roche markets Evrysdi (risdiplam), the leading oral SMA therapy and Zolgensma's principal competitive threat. Roche also owns Spark Therapeutics (Luxturna), giving it breadth across both small-molecule and AAV gene therapy modalities for rare diseases.
• Pfizer: Pfizer invested aggressively in AAV gene therapy for DMD and hemophilia, and despite setbacks remains a broad incumbent competitor in the rare-disease gene therapy space with overlapping commercial and manufacturing capabilities.

Emerging players

• Solid Biosciences: Solid Biosciences is a clinical-stage AAV gene therapy company focused on DMD and other rare neuromuscular diseases. While smaller and narrower in indication, its AAV platform and neuromuscular focus overlap with AveXis's core technology.
• Taysha Gene Therapies: Taysha is a clinical-stage AAV gene therapy company developing treatments for CNS and rare neurological diseases, often in partnership with larger pharma. Its AAV platform and CNS focus overlap directly with AveXis's neurodegenerative pipeline direction.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/avexisinc
• Facebookfacebook.com/554499151263809
• LinkedInlinkedin.com/company/avexis-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AveXis